STOCK TITAN
  1. Home
  2. Sec-filings
  3. RANI
  4. [424B5] Rani Therapeutics Holdings, Inc. Prospectus Supplement (Debt Securities)

[424B5] Rani Therapeutics Holdings, Inc. Prospectus Supplement (Debt Securities)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B5
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock RANI logo
Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

RANI Rankings

#6802 Ranked by Market Cap
N/A Ranked by Dividends

RANI Latest News

Jul 15, 2025
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
Jul 14, 2025
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery 
May 19, 2025
Rani Therapeutics Announces Research Agreement with Chugai
May 13, 2025
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update
Mar 31, 2025
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

RANI Latest SEC Filings

Jul 16, 2025
[8-K] Rani Therapeutics Holdings, Inc. Reports Material Event
Jul 14, 2025
[EFFECT] Rani Therapeutics Holdings, Inc. SEC Filing
Jul 11, 2025
[424B5] Rani Therapeutics Holdings, Inc. Prospectus Supplement (Debt Securities)
Jul 10, 2025
[DEF 14C] Rani Therapeutics Holdings, Inc. Definitive Information Statement
Jul 3, 2025
[S-3] Rani Therapeutics Holdings, Inc. Shelf Registration Statement

RANI Stock Data

23.60M
29.87M
27.31%
10.85%
7.4%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN JOSE